John B. Porter

20.7k total citations · 2 hit papers
468 papers, 14.2k citations indexed

About

John B. Porter is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, John B. Porter has authored 468 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Genetics, 274 papers in Hematology and 72 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in John B. Porter's work include Hemoglobinopathies and Related Disorders (338 papers), Iron Metabolism and Disorders (214 papers) and Blood groups and transfusion (57 papers). John B. Porter is often cited by papers focused on Hemoglobinopathies and Related Disorders (338 papers), Iron Metabolism and Disorders (214 papers) and Blood groups and transfusion (57 papers). John B. Porter collaborates with scholars based in United Kingdom, United States and Italy. John B. Porter's co-authors include Robert C. Hider, Maria Domenica Cappellini, Alì Taher, Bernard A. Davis, Dudley J. Pennell, Vip Viprakasit, Maciej Garbowski, Alan R. Cohen, E. R. Huehns and John M. Walker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

John B. Porter

453 papers receiving 13.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)

2014 303 citations Maria Domenica Cappellini, John B. Porter et al. profile →
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia

2022 117 citations John B. Porter, Alì Taher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John B. Porter United Kingdom	64	9.6k	9.1k	2.1k	2.0k	1.5k	468	14.2k
Alì Taher Lebanon	58	9.9k 1.0×	9.7k 1.1×	867 0.4×	1.9k 0.9×	1.1k 0.7×	533	14.6k
Victor R. Gordeuk United States	57	6.6k 0.7×	6.5k 0.7×	2.0k 1.0×	1.1k 0.5×	1.8k 1.2×	401	11.8k
Maria Domenica Cappellini Italy	70	14.0k 1.5×	12.5k 1.4×	1.6k 0.8×	4.0k 2.0×	2.8k 1.9×	565	20.8k
Antonio Piga Italy	44	6.7k 0.7×	6.1k 0.7×	1.2k 0.6×	1.6k 0.8×	626 0.4×	195	8.8k
Nancy F. Olivieri Canada	51	7.3k 0.8×	6.4k 0.7×	1.1k 0.5×	2.1k 1.0×	1.0k 0.7×	169	9.4k
Clara Camaschella Italy	60	8.5k 0.9×	10.5k 1.2×	5.7k 2.8×	726 0.4×	2.4k 1.6×	249	14.9k
Iain C. Macdougall United Kingdom	49	3.1k 0.3×	6.6k 0.7×	704 0.3×	633 0.3×	1.7k 1.1×	187	12.0k
Ellis J. Neufeld United States	58	2.8k 0.3×	4.2k 0.5×	674 0.3×	1.2k 0.6×	2.1k 1.4×	241	10.4k
Lawrie W. Powell Australia	63	6.3k 0.7×	8.6k 0.9×	5.8k 2.8×	463 0.2×	1.4k 0.9×	295	14.2k
David G. Nathan United States	64	5.8k 0.6×	6.2k 0.7×	508 0.2×	2.2k 1.1×	3.4k 2.2×	296	14.7k

Countries citing papers authored by John B. Porter

Since Specialization

Citations

This map shows the geographic impact of John B. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Porter more than expected).

Fields of papers citing papers by John B. Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Porter. The network helps show where John B. Porter may publish in the future.

Co-authorship network of co-authors of John B. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of John B. Porter. A scholar is included among the top collaborators of John B. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B. Porter. John B. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taher, Alì, Vip Viprakasit, Antonis Kattamis, et al.. (2025). Efficacy and safety of luspatercept in non–transfusion-dependent β-thalassemia: long-term results from the BEYOND study. Blood Advances. 9(23). 6108–6119.

Reisch, Nicole, Wiebke Arlt, Aude Brac de la Perrière, et al.. (2023). Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology. 188(1). 109–117. 7 indexed citations

Walters, Mark C., Janet L. Kwiatkowski, John B. Porter, et al.. (2021). Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies. Transplantation and Cellular Therapy. 27(3). S112–S114. 1 indexed citations

Hongeng, Suradej, Alexis A. Thompson, Janet L. Kwiatkowski, et al.. (2021). Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion. Transplantation and Cellular Therapy. 27(3). S1–S1. 1 indexed citations

Thompson, Alexis A., Franco Locatelli, Evangelia Yannaki, et al.. (2021). Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up. Blood. 138(Supplement 1). 573–573. 2 indexed citations

Thompson, Alexis A., Janet L. Kwiatkowski, John B. Porter, et al.. (2020). Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia. Blood. 136(Supplement 1). 52–54. 7 indexed citations

Howard, Jo, Claire Hemmaway, Paul Telfer, et al.. (2019). A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 133(17). 1865–1875. 84 indexed citations

Eleftheriou, Perla, et al.. (2018). Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis. Blood. 132(Supplement 1). 3666–3666. 1 indexed citations

Neumann, Uta, Martin J. Whitaker, Susanna Wiegand, et al.. (2017). Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clinical Endocrinology. 88(1). 21–29. 42 indexed citations

10.

Cappellini, Maria Domenica, John B. Porter, Khaled M. Musallam, et al.. (2015). Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine. 28. 91–96. 10 indexed citations

11.

Pennell, Dudley J., John B. Porter, Antonio Piga, et al.. (2014). A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 123(10). 1447–1454. 95 indexed citations

12.

Carpenter, John‐Paul, Agata Grasso, John B. Porter, et al.. (2013). On myocardial siderosis and left ventricular dysfunction in hemochromatosis. Journal of Cardiovascular Magnetic Resonance. 15(1). 24–24. 25 indexed citations

13.

Taher, Alì, John B. Porter, Vip Viprakasit, et al.. (2012). Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 120(5). 970–977. 109 indexed citations

14.

Phisalaphong, Chada, Narissara Lailerd, Nipon Chattipakorn, et al.. (2010). Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids. Medicinal Chemistry. 7(1). 62–69. 33 indexed citations

15.

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2010). CONTINUED IMPROVEMENT IN CARDIAC T2*WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS. UCL Discovery (University College London). 2 indexed citations

16.

Anderson, Lisa, Sally Holden, David Firmin, et al.. (2000). A novel method of cardiac iron measurement using magnetic resonance T2*imaging in thalassemia: Validation and clinical application. UCL Discovery (University College London). 1 indexed citations

17.

Porter, John B., et al.. (1998). Endothelial activation in patients with chronic disease. UCL Discovery (University College London). 1 indexed citations

18.

Porter, John B., Iman Hassan, Christopher M. Reid, et al.. (1997). Subcutaneous depot desferrioxamine (CGH 749B); Relationship of pharmacokinetics to efficacy and drug metabolism.. UCL Discovery (University College London). 3 indexed citations

19.

Alberti, Dona, et al.. (1997). Efficacy of a new formulation of desferrioxamine (CGH 749B) given as subcutaneous bolus injections in transfusion-dependent beta-thalassemic patients.. UCL Discovery (University College London). 1 indexed citations

20.

Dobbin, Paul S., Robert C. Hider, Paul Taylor, et al.. (1993). Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. Journal of Medicinal Chemistry. 36(17). 2448–2458. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact